A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2016
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 28 Jun 2016 Status changed from active, no longer recruiting to completed.
- 31 May 2016 Status changed from recruiting to active, no longer recruiting.